

## Message from the Editor-in-Chief

I have some good news for our members.

The Impact Factor for 2021 has been released. Reproductive Medicine and Biology (RMB) scored 4.009, much higher than last year's 3.239. It ranked highly at 21 out of 85 in the Obstetrics & Gynecology category and 11 out of 31 in the Reproductive Biology category. This is owing to the support of our members. Thank you very much.

The first issue of RMB was published in 2002 as the official journal of the Japan Society for Reproductive Medicine, Japan Society of Fertilization and Implantation, and Japan Society of Andrology. In 2016 the Asian Society of Endometriosis & Adenomyosis, and in 2020 the Japan Society for Ova Research also joined.

The numbers of submissions and papers published have risen steadily, and today the journal publishes more than 60 high-quality invited reviews and original articles a year. Moreover, all papers published since the first issue in 2002 can be searched in PubMed. <https://www.ncbi.nlm.nih.gov/pmc/journals/3326/>

Japan is a global leader in reproductive medicine with over 400 thousand assisted reproductive treatment (ART) cycles performed yearly. As members of the Japanese reproductive medicine and medical science community, it is our critical mission to further improve our country's reproductive medicine and medical science and share the information with the world. For Japan to lead the world forward in reproductive medicine and medical science, I believe it is important to keep expanding RMB as a tool for sharing information from Japan. I ask for your continued support as we endeavor to further evolve RMB as a world-class international English-language journal of reproductive medicine and medical science.

July 2022

Norihiro Sugino

Editor-in-Chief, RMB

Board Member in charge of editing, Japan Society for Reproductive Medicine